PGNY on Nasdaq

Progyny, Inc.

Logo: progyny.com3

Fertility benefits management company.1

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Sotera Health Co, Tivity Health or agilon health, inc., or pick any stock.

  • TickerPGNY on Nasdaq1
  • IndustryServices-Misc Health & Allied Services, NEC1
  • HeadquartersNew York, New York1
  • Websiteprogyny.com
  • Incorporated inDE4
  • Business address1359 Broadway, 2Nd Floor, New York, Ny 100184
  • Filer categoryLarge accelerated filer4

See how the biggest companies compare on our leaderboards

Progyny is a global leader in women’s health and family building solutions. We envision a world where everyone can realize their dreams of family and ideal health. Our mission is to empower healthier, supported journeys through transformative fertility, family building and women’s health benefits. Through our differentiated approach to benefits plan design, member education and support and active network management, our clients’ employees are able to pursue the most effective treatment across life’s milestones from the best providers and specialists and achieve optimal outcomes.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

23.6%Gross margin6
6.6%Operating margin6
4.5%Net margin6
10.4%Revenue growth, 20256
11.3%Return on equity6
$191.8MFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Fertility benefit services revenue brought in 64% of the revenue Progyny, Inc. broke down this way in fiscal 2025.

  1. Fertility benefit services revenue$830.9M664%up 14% from 2024
  2. Pharmacy benefit services revenue$457.7M636%up 5% from 2024
Products and services by year
Products and services202320242025
Fertility benefit services revenue$676.3M$729.6M$830.9M
Pharmacy benefit services revenue$412.3M$437.7M$457.7M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue76¢$984.2M
  • Research and development1¢$9.5M
  • Other costs15¢$199.6M
  • Income tax3¢$36.9M
  • Profit5¢$58.5M

Out of $1.3B in revenue.6

Where each dollar of operating cash went, fiscal 2025

  • Capital spending9¢$18.4M
  • Share buybacks39¢$81.7M
  • Kept or used elsewhere52¢$110.1M

Out of $210.2M of cash from operations.6

Financial statements

Revenue789106$1.3B in 2025+461% since 2019
0$500.0M$1.0B$1.5B2019: $229.7M$229.7M20192020: $344.9M$344.9M2020+50%2021: $500.6M$500.6M2021+45%2022: $786.9M$786.9M2022+57%2023: $1.1B$1.1B2023+38%2024: $1.2B$1.2B2024+7%2025: $1.3B$1.3B2025+10%
Gross profit789106$304.5M in 2025+569% since 2019
0$100.0M$200.0M$300.0M$400.0M2019: $45.5M$45.5M20192020: $70.1M$70.1M2020+54%2021: $112.1M$112.1M2021+60%2022: $167.3M$167.3M2022+49%2023: $238.8M$238.8M2023+43%2024: $253.4M$253.4M2024+6%2025: $304.5M$304.5M2025+20%
Operating income789106$85.3M in 2025+781% since 2019
0$25.0M$50.0M$75.0M$100.0M2019: $9.7M$9.7M20192020: $8.3M$8.3M2020−14%2021: $32.3M$32.3M2021+287%2022: $23.3M$23.3M2022−28%2023: $62.2M$62.2M2023+166%2024: $67.5M$67.5M2024+8%2025: $85.3M$85.3M2025+26%
Net income789106$58.5M in 2025
-$20.0M0$20.0M$40.0M$60.0M$80.0M2019: -$8.6M-$8.6M20192020: $46.5M$46.5M20202021: $65.8M$65.8M2021+42%2022: $30.4M$30.4M2022−54%2023: $62.0M$62.0M2023+104%2024: $54.3M$54.3M2024−12%2025: $58.5M$58.5M2025+8%

Every line of the income statement as filed: the last 3 fiscal years (annual) or 8 quarters (quarterly), latest first.6

Period ending2025-12-312024-12-312023-12-31
Revenue$1.3B$1.2B$1.1B
Cost of services$984.2M$913.9M$849.8M
Gross profit$304.5M$253.4M$238.8M
Sales and marketing$72.1M$63.9M$59.5M
General and administrative$147.1M$122.0M$117.1M
Total operating expenses$219.2M$185.9M$176.6M
Income from operations$85.3M$67.5M$62.2M
Interest and other income, net$10.2M$15.7M$8.5M
Income before income taxes$95.4M$83.2M$70.7M
Provision for income taxes$36.9M$28.9M$8.7M
Net income$58.5M$54.3M$62.0M
Basic (in dollars per share)$0.68$0.59$0.65
Diluted (in dollars per share)$0.65$0.57$0.62
Basic (in shares)85.7M shares91.5M shares95.0M shares
Diluted (in shares)89.9M shares95.4M shares100.7M shares

Compare Progyny, Inc. with another company

The story

Founded by Gina Bartasi.1

Leadership

Who has led Progyny, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. David J. Schlanger2019–2021
  2. Peter Anevski2022–now

Chair

  1. David J. Schlanger2022–now

President

  1. Peter Anevski2020–2021
  2. Michael E. Sturmer2022–now

Chief financial officer

  1. Mark S. Livingston2020–now

Chief operating officer

  1. Peter Anevski2020–2021
20202025
Board members and other officers (20)

Former names

  • Auxogyn, Inc.Mar 19, 2015 to Mar 19, 20154
  • Auxogyn IncJun 4, 2012 to Sep 16, 20134

Timeline

  1. Jan 3, 2022New chief executive Peter Anevski becomes CEO14
  2. Oct 24, 2019New chief executive David J. Schlanger becomes CEO15
  3. 2019Went public Listed on NASDAQ1

Filings

564 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 43 major events, 395 insider forms, 29 large holders, 77 other. The latest 20:

  1. Oct 14, 2026144 EDGAR
  2. Sep 28, 20264 EDGAR
  3. Sep 23, 2026144 EDGAR
  4. Sep 21, 20264 EDGAR
  5. Sep 18, 20264/A EDGAR
  6. Sep 14, 20264 EDGAR
  7. Sep 10, 2026144 EDGAR
  8. Sep 8, 20264 EDGAR
  9. Sep 8, 20264 EDGAR
  10. Sep 8, 20264 EDGAR
  11. Sep 4, 20264 EDGAR
  12. Sep 1, 20264 EDGAR
  13. Aug 7, 202610-Q EDGAR
  14. Aug 6, 20268-K EDGAR
  15. Aug 6, 2026SCHEDULE 13G/A EDGAR
  16. Jul 16, 20264 EDGAR
  17. Jul 14, 2026144 EDGAR
  18. Jun 23, 20264 EDGAR
  19. Jun 8, 2026SCHEDULE 13G/A EDGAR
  20. Jun 5, 20264 EDGAR

The 564 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

293 open-market trades by officers, directors and large owners since October 2021: 3 buys and 290 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 23, 2026Swartz AllisonEVP, GCSale3,903$26.10$101.9KForm 4
Sep 10, 2026GORDON KEVIN KDirectorSale11,500$27.12$311.9KForm 4
Sep 10, 2026GORDON KEVIN KDirectorSale11,500$27.94$321.3KForm 4
Jul 14, 2026Cummings Melissa BChief Operating OfficerSale2,244$31.60$70.9KForm 4
Jun 4, 2026Livingston Mark S.CHIEF FINANCIAL OFFICERSale2,517$25.50$64.2KForm 4
Jun 4, 2026Swartz AllisonEVP, GCSale599$25.08$15.0KForm 4
Jun 3, 2026Swartz AllisonEVP, GCSale1,199$25.02$30.0KForm 4
Jun 2, 2026Livingston Mark S.CHIEF FINANCIAL OFFICERSale279$26.20$7.3KForm 4
Jun 2, 2026Clapp GeoffreyChief Product OfficerSale1,530$25.58$39.1KForm 4
Jun 1, 2026Scott CherylDirectorSale7,439$26.39$196.3KForm 4
May 28, 2026Swartz AllisonEVP, GCSale2,398$25.46$61.1KForm 4
May 27, 2026GORDON KEVIN KDirectorSale5,500$24.99$137.4KForm 4
May 20, 2026Livingston Mark S.CHIEF FINANCIAL OFFICERSale8,275$25.50$211.0KForm 4
May 19, 2026Cummings Melissa BChief Operating OfficerSale9,578$25.00$239.4KForm 4
Mar 4, 2026Swartz AllisonEVP, GCSale599$17.54$10.5KForm 4
Mar 3, 2026Swartz AllisonEVP, GCSale4,657$17.40$81.0KForm 4
Mar 2, 2026Swartz AllisonEVP, GCSale2,199$17.27$38.0KForm 4
Dec 11, 2025Livingston Mark S.CHIEF FINANCIAL OFFICERSale459$25.50$11.7KForm 4
Dec 4, 2025Swartz AllisonEVP, GCSale530$24.59$13.0KForm 4
Dec 2, 2025Livingston Mark S.CHIEF FINANCIAL OFFICERSale213$25.50$5.4KForm 4

All 293 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.11,599,921$334.4M0.0%−398,546
Fmr LLC7,004,280$201.9M0.0%+503,461
Vanguard Portfolio Management LLC5,019,465$144.7M0.0%−272,563
Vanguard Capital Management LLC3,210,723$92.6M0.0%−270,616
State Street Corp3,022,859$87.1M0.0%−57,434
Ameriprise Financial Inc2,763,514$79.7M0.0%−61,817
Fort Washington Investment Advisors Inc /oh/2,548,164$73.5M0.4%−145,229
Geode Capital Management, LLC1,969,208$56.8M0.0%−73,757
Citadel Advisors LLC1,785,717$51.5M0.0%New
Dimensional Fund Advisors LP1,688,670$48.7M0.0%+115,245
Soleus Capital Management, L.P.1,602,000$46.2M1.6%−465,000
Morgan Stanley1,535,897$44.3M0.0%−751,720
Wellington Management Group Llp1,496,633$43.1M0.0%−790,748
Disciplined Growth Investors Inc /mn1,181,632$34.1M0.6%+607,066
Loomis Sayles & Co L P1,080,928$31.2M0.0%+92,538
Baillie Gifford & Co1,078,629$31.1M0.0%−142,100
Jane Street Group, LLC1,063,363$30.7M0.0%+914,457
Easterly Investment Partners LLC958,117$27.6M1.4%+124,669
Charles Schwab Investment Management Inc954,065$27.5M0.0%+155,441
Northern Trust Corp802,885$23.1M0.0%−15,291
Aqr Capital Management LLC797,534$23.0M0.0%+141,140
American Century Companies Inc778,839$22.5M0.0%+553,047
Fideuram Asset Management (Ireland) dac904,062$18.4M0.4%+823,237
River Road Asset Management, LLC635,023$18.3M0.2%−41,204
Nuveen, LLC606,955$17.5M0.0%+19,192

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

5 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Dec 6, 2024Josh GottheimerDemocratic, HouseSale$1,001 - $15,000−59.0%Report
Jul 30, 2020Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−133.6%Report
Jun 30, 2020Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−143.9%Report
Jun 1, 2020Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−138.2%Report
May 21, 2020Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−151.6%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
    Company websiteProgyny, Inc. logo
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47